Key result
Current and former smoking linked to MACE occurring ~9 months earlier after PCI.
Why the study?
The smoker's paradox describes an unexpectedly favorable short-term outcome of smokers post-PCI, but it remains a controversial phenomenon.
Does current or ex-smoking status improve or reduce the time to recurrent major adverse cardiovascular events in patients following percutaneous coronary intervention compared to non-smokers?
Cohort (n=22,741)
Yes
Does current or ex-smoking status improve or reduce the time to recurrent major adverse cardiovascular events in patients following percutaneous coronary intervention compared to non-smokers?
In patients undergoing PCI, the 'smoker's paradox' was not observed after propensity score adjustment; current and ex-smokers developed recurrent MACEs significantly earlier than non-smokers.
Smoking history was associated with earlier recurrent MACE after PCI; challenges smoker's paradox yet leaves open causality pending prospective confirmation.
Background “Smoker's paradox” is a controversial phenomenon that describes an unexpectedly favorable short-term outcome of smokers post-percutaneous coronary intervention (PCI). This study aimed to evaluate the effect of smoking status on recurrent major adverse cardiovascular events (MACEs) in patients who recently underwent PCI and to determine whether it was paradoxical. Methods This study utilized data from the nationwide Thai PCI registry, enrolling patients during 2018–2019. Our study factor was smoking status, classified as current smokers, ex-smokers, and nonsmokers. The outcome of interest was the time to occurrence of a composite of MACEs (i.e., all-cause death, myocardial infarction (MI), stroke, and unplanned revascularization) evaluated at about 1-year post-PCI. A propensity score (PS) model using inverse probability weighting with regression adjustment was used to estimate the effect of smoking on the occurrence of MACE. Results Current smokers, ex-smokers, and non-smokers accounted for 23, 32, and 45% of the 22,741 subjects, respectively. Smokers were younger, more frequently male, and had fewer traditional atherosclerotic risk factors. Current smokers presented more frequently with ST-elevation MIs (STEMIs) and cardiogenic shock (54 and 14.6%, respectively) than non-smokers. MACE rates were 1.9, 1.2, and 1.6 per 100 patients per month in the current smokers, ex-smokers, and non-smokers, respectively. After applying a PS, patients with a history of current smoking and ex-smoking developed the onset of recurrent MACEs significantly sooner than non-smokers, with a median time of 4.4 vs. 4.9 vs. 13.5 months ( p < 0.001), respectively. Conclusions “Smoker's paradox” was not observed in our patient population. Current smokers and ex-smokers were prone to develop an earlier onset of a post-PCI MACEs than nonsmokers and need a smoke cessation program for further prevention.
No takes yet. Share an insight, caveat, or question.
Limpijankit et al. (2022) conducted a cohort in Patients following percutaneous coronary intervention (PCI) (n=22,741). Current smoking vs. Non-smokers was evaluated on Time to occurrence of a composite of MACEs (all-cause death, myocardial infarction, stroke, and unplanned revascularization) (ATE -9.12, 95% CI -14.23, -4.02, p=<0.001). Current smokers and ex-smokers developed major adverse cardiovascular events significantly sooner than non-smokers after percutaneous coronary intervention (median 4.4 and 4.9 vs 13.5 months).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: